Duke Cardiology fellow Matt Sherwood interviews Dr. David Holmes on the PREVAIL trial results, embargo breaks, and how the WATCHMAN device will fare in the future. Get insights on this controversial issue at ACC.13.
US-based clinical registries, such as the National Cardiovascular Data Registry and Get With The Guidelines, have been instrumental in identifying and addressing gaps in quality of care for patients across the country. It is fascinating to see approaches in other countries who have developed nationwide clinical registries, inclusive of all citizens. In Sweden, clinical registries like SCAAR and SWEDEHEART, have not only been used to describe trends in nationwide clinical outcomes but are now being used as a platform for the conduct of randomized trials. With rich characterization of patients and longitudinal followup, clinical registries can be used to identify, enroll, and follow patients randomized to treatments or strategies of care that need more investigation. These innovative “randomized clinical registry studies” are being conducted in the US as well. We need more of them.
John chats with Zubin about his work in the NCDR-ICD registry. Zubin and his colleagues found that although rates of CRT implantation are improving in the overall population, disparities in care persist.
Dr. Kenneth Mahaffey presented the eagerly awaited results from ROCKET AF, which showed that the new oral factor Xa inhibitor rivaroxaban met its primary efficacy end point of noninferiority to dose-adjusted warfarin with regard to all-cause stroke and non-central nervous system systemic embolism. Again, this was a packed session as you can see below.
Dr. Mahaffey presents the results of ROCKET AF
Dr. Mahaffey convenes with Drs. Rob Califf and Manesh Patel aftewards
Here are the ROCKET-AF slides presented by Dr. Mahaffey.
Dr. Manesh Patel presented the findings at the "Meet the Trialists" session.
A large crowd gathered to hear the results in detail.
Today’s oral abstract session on cell therapy has been very well attended, including by many of the thought leaders in the field (Dr. Chuck Murry, Dr. Rich Lee, and Dr Eduardo Marban to name a few). Lots of fascinating pre-clinical studies and small clinical studies looking at cell therapy benefits in patients with heart failure. One interesting abstract from Dr. Nenad Bursac’s group from
Duke seems to be headed towards developing cellular patches with pacing potential. Lots of good questions on mechanism of benefit, choice of cell type, delivery strategies, and safety. The audience seems to have mixed feelings on whether this research is ready for primetime.